CSPI:NASDAQCSP Inc. Analysis
Data as of 2026-06-17 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
CSP Inc. is trading at $9.34, just above its 20‑day (9.31) and 50‑day (9.30) simple moving averages but still below the 200‑day SMA of $10.71, indicating a short‑term bias that is not yet confirmed by longer‑term momentum. The RSI of 52 and a bullish MACD histogram (+0.003) suggest modest upside pressure, while the recent increase in volume adds confidence to the technical signal. However, the stock’s 30‑day volatility of 46% and a beta of 1.46 point to a highly volatile profile that could amplify price swings. On the fundamentals side, revenue jumped 22% year‑over‑year to $57.96 M, yet operating margins are negative (‑5.3%) and the company posted a small loss per share (‑$0.01), leaving the PE ratio at zero. The balance sheet shows $23.1 M of cash against $2.1 M of debt, giving a comfortable liquidity cushion but the negative free cash flow (‑$2.14 M) raises concerns about cash burn. The dividend yield of 1.27% is modest and the payout ratio is only 5.8%, but the lack of earnings makes the dividend’s sustainability questionable. Overall, the stock sits in a neutral technical zone with strong revenue growth offset by profitability challenges, high volatility, and modest valuation metrics.
Market Outlook
Short Term
< 1 yearKey Factors
- Bullish MACD crossover with positive histogram
- Price trading just above short‑term SMAs
- High short‑term volatility and proximity to resistance at $10.10
Medium Term
1–3 yearsKey Factors
- Revenue growth of 22% indicating top‑line momentum
- Strong cash position relative to debt
- Low dividend payout ratio providing room for reinvestment
Long Term
> 3 yearsKey Factors
- Persistently negative operating and net margins
- Elevated beta and volatility suggesting price instability
- Potential upside from defense and security contracts but uncertain profitability
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.